🇺🇸 FDA

Company profile · Sponsor

Enliven

Enliven Therapeutics

ELVN · NYSE pharma BOULDER, CO, USA
Pipeline
6
Drugs
0
Patents
5

Quick answer

Enliven (ELVN) is a pharma company. headquartered in BOULDER, CO, USA. listed on NYSE. NovaPharmaNews links 6 pipeline programs, 0 drugs, and 5 patents to this profile..

Company facts

Ticker ELVN
Exchange NYSE
Company type pharma
Headquarters BOULDER, CO, USA
SEC CIK 0001672619

Pipeline (6)

Search pipeline →

  1. 5-FU medac 50 mg/ml, Injektionslösung, ELVN-002, BENDAFOLIN 10 mg/ml Injektionslösung, ELVN-002, ELVN-002, ELVN-002, ELVN-002, Benda-5 FU 50 mg/ml Injektionslösung, Oxaliplatin AqVida 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, ELVN-002, Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, HALAVEN 0.44 mg/ml solution for injection, Capecitabin "Zentiva", filmovertrukne tabletter, ELVN-002, Herceptin 150 mg powder for concentrate for solution for infusion, Capecitabine Ac

    Enliven

    Solid Tumors, Colorectal Cancer and Breast Cancer

    phase 2 small molecule active

    1 trial

  2. A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia

    Enliven

    Chronic myeloid leukemia

    phase 1 other active

    1 trial

  3. ELVN-001

    Enliven

    Chronic Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  4. ELVN-001

    Enliven

    CML (Chronic Myelogenous Leukemia)

    phase 1 small molecule active

    1 trial

  5. ELVN-002

    Enliven

    HER2 Mutant Non-small Cell Lung Cancer

    phase 1 small molecule active

    1 trial

  6. ELVN-002

    Enliven

    HER2-positive Breast Cancer

    phase 1 small molecule active

    1 trial

Patents (5)

Search patents →

  1. US 12240846

    5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases

    Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11807638

    5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases

    Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11807649

    Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2

    Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11767321

    5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases

    Expires Mon Sep 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10888597

    Composition for treating brain stroke

    Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Enliven?

Enliven (ELVN) is a pharma company. headquartered in BOULDER, CO, USA. listed on NYSE. NovaPharmaNews links 6 pipeline programs, 0 drugs, and 5 patents to this profile..

What pipeline programs does Enliven sponsor?

We track 6 ClinicalTrials.gov-linked programs for Enliven, including 5-FU medac 50 mg/ml, Injektionslösung, ELVN-002, BENDAFOLIN 10 mg/ml Injektionslösung, ELVN-002, ELVN-002, ELVN-002, ELVN-002, Benda-5 FU 50 mg/ml Injektionslösung, Oxaliplatin AqVida 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, ELVN-002, Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, HALAVEN 0.44 mg/ml solution for injection, Capecitabin "Zentiva", filmovertrukne tabletter, ELVN-002, Herceptin 150 mg powder for concentrate for solution for infusion, Capecitabine Ac and 5 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Enliven company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.